AOD-9604: The “Fat Loss” Fragment: Rodent Results vs. Human Trials
Last updated: October 2026
AOD-9604 is a synthetic peptide corresponding to amino acids 177โ191 of human growth hormone (plus an added tyrosine), the C-terminal region linked to growth hormone's lipolytic activity. In obese rodents it raised lipolysis markers and reduced weight gain and body fat. In human trials it did not raise IGF-1 or impair glucose tolerance; a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo. Not FDA-approved.
(no significant weight loss)
(Tyr + hGH 177โ191)
Human Trials
AOD-9604 is a synthetic peptide matching amino acids 177โ191 of human growth hormone, plus an added tyrosine, studied for fat loss. A 12-week trial reported 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo, but a larger 24-week trial showed no significant weight loss vs placebo. It is not FDA-approved.
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
What Is AOD-9604?
AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of the growth hormone sequence plus an added tyrosine (the C-terminal region linked to growth hormone's lipolytic activity), designed to avoid its growth-promoting effects.
In obese mice and rats, AOD-9604 increased markers of lipolysis (the breakdown of stored fat) and fat oxidation and reduced weight gain. In humans, a 12-week randomized trial reported an average 2.6 kg loss on 1 mg/day vs 0.8 kg on placebo (no dose-response: 10 mg/day lost less), but a larger 24-week trial did not show a significant weight-loss benefit over placebo.
In sponsor-run human trials, AOD-9604 did not raise serum IGF-1 or impair glucose tolerance, unlike full-length HGH. In lab assays it did not bind the growth hormone receptor or drive cell proliferation.
AOD-9604 was designed to keep growth hormone's anti-lipogenic signalling: slowing the synthesis and storage of fat (lipogenesis), not the creation of new fat cells. Human data showing a meaningful effect are lacking.
Human trials tested oral and intravenous dosing; subcutaneous injection is what online protocols describe. Sponsor-reported trials found tolerability similar to placebo, but no long-term safety data exist.
What the Research Shows
Animal and human data on AOD-9604: a 12-week human trial reported more weight loss than placebo on 1 mg/day, but the rodent fat-loss signal was not confirmed in a larger 24-week trial.
Key Takeaways
- HGH fragment (amino acids 177-191)
- Raised lipolysis markers and cut weight gain in obese rodents
- Did not raise IGF-1 or impair glucose tolerance in human trials
- A 12-week trial reported 2.6 kg vs 0.8 kg loss (1 mg/day, no dose-response); a larger 24-week trial showed no significant weight loss vs placebo
- Did not bind the GH receptor or drive cell proliferation in lab assays
- Limited peer-reviewed human efficacy data (mostly sponsor-reported)
- Not FDA approved in US
- Optimal dosing protocols not established
- Long-term safety unknown
Verified Research Source
Research compounds from Swiss Chems, our affiliate supplier.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Related Resources
Research-Grade Peptides
Research compounds from Swiss Chems, our affiliate supplier; vendor-published COAs for selected products.
Browse Swiss Chems โAffiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
This page is for educational purposes only. AOD-9604 is not FDA approved. Always consult a healthcare provider.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.